Miglustat
Klinički podaci | |
---|---|
Prodajno ime | Miglustat, Hydrochloride, Zavesca |
Drugs.com | Monografija |
Način primene | Oralno |
Farmakokinetički podaci | |
Poluvreme eliminacije | 6 do 7 sati |
Identifikatori | |
CAS broj | 72599-27-0 Y |
ATC kod | A16AX06 (WHO) |
PubChem | CID 51634 |
DrugBank | DB00419 Y |
ChemSpider | 46764 Y |
ChEBI | CHEBI:50381 Y |
ChEMBL | CHEMBL1029 Y |
Hemijski podaci | |
Formula | C10H21NO4 |
Molarna masa | 219,278 |
SMILES
| |
InChI
| |
Fizički podaci | |
Tačka topljenja | 169—172 °C (336—342 °F) |
Miglustat je organsko jedinjenje, koje sadrži 10 atoma ugljenika i ima molekulsku masu od 219,278 Da.[1][2][3][4][5][6][7][8]
Osobine
Osobina | Vrednost |
---|---|
Broj akceptora vodonika | 5 |
Broj donora vodonika | 4 |
Broj rotacionih veza | 4 |
Particioni koeficijent[9] (ALogP) | -0,6 |
Rastvorljivost[10] (logS, log(mol/L)) | -0,1 |
Polarna površina[11] (PSA, Å2) | 84,2 |
Reference
- ^ van Giersbergen PL, Dingemanse J: Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol. 2007 Oct;47(10):1277-82. Epub 2007 Aug 24. PMID 17720777
- ^ Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9. PMID 16247743
- ^ Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE: Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007 Sep;6(9):765-72. PMID 17689147
- ^ Moyses C: Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955-60. PMID 12803929
- ^ Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-87. Epub 2009 Nov 18. PMID 19956552
- ^ McCormack PL, Goa KL: Miglustat. Drugs. 2003;63(22):2427-34; discussion 2435-6. PMID 14609352
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. уреди
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. уреди
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. уреди
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. уреди
Literatura
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
- Miglustat
Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |